The power of CyTOF in the pandemic: How mass cytometry is driving COVID-19 research

Join this webinar to discover how cytometry can be used to monitor immune responses to new therapeutics and how the Maxpar Direct Immune Profiling System can help meet the demands of your COVID-19 research

23 Apr 2020

Tom Casburn

Associate Editor

Dr. Andrew Quong and Dr. Roberto Spada, Fluidigm

The COVID-19 public health crisis affects everyone in our global community. Crucial questions about how SARS-CoV-2 affects our immune system and how to monitor the response to newly developed therapeutic interventions must be answered, and quickly.

In this upcoming webinar, Dr. Andrew Quong, Chief Science Officer at Fluidigm, will describe the important role that cytometry is playing in these efforts as well as how researchers are already using mass cytometry to monitor the immune response to a COVID-19 therapeutic approach. In addition, he will explain the Maxpar^® Direct™ Immune Profiling System: a fast, reliable cytometric assay that includes an automated data analysis solution designed for use on CyTOF^® systems.

Dr. Roberto Spada, Senior Market Development Manager, will share results of a multi-site study with the Maxpar^® Direct™ Immune Profiling System that illustrates the inter-site and intra-site reproducibility of the assay. He will also present data showing that samples processed with the assay can be cryopreserved for up to four months without adverse impact on immune cell subset identification and enumeration.

The live webinar takes place on Monday, May 4, 2020, at: